-
Stay Connected
Get the latest news on exciting speakers, workshops & learning opportunities at ISDE 2021.
Subscribe for Updates
Barrett’s esophagus develops when chronic gastroesophageal reflux damages the normal lining of the esophagus and causes specialized intestinal-type cells to appear. This condition can increase the risk of esophageal adenocarcinoma, although most people with Barrett’s will never develop cancer. Management usually combines reflux control, surveillance endoscopy, and treatment of precancerous changes when they arise.
Chemoprevention refers to using a medication or compound to reduce the chance that abnormal tissue will progress. Aspirin has attracted interest because it affects inflammation and platelet activity, two biological processes that may contribute to cancer development. Research has examined whether regular aspirin use could add protection for selected people with Barrett’s esophagus.
Long-term irritation from acid reflux can create an inflammatory environment in the esophageal lining. Aspirin inhibits cyclooxygenase enzymes involved in prostaglandin production, which may reduce inflammatory signaling. It also influences platelet behavior and pathways associated with abnormal cell growth. These effects provide a scientific rationale for studying aspirin as a preventive therapy.
The idea is not that aspirin reverses Barrett’s tissue or replaces acid suppression. Instead, it has been investigated as a possible additional measure that might lower the risk of high-grade dysplasia or esophageal adenocarcinoma over time. The potential benefit must be weighed against aspirin’s recognized harms, especially gastrointestinal bleeding.
The AspECT randomized trial evaluated high- and low-dose proton pump inhibitor therapy, with or without aspirin, in people with Barrett’s esophagus. Its results suggested that high-dose acid suppression offered greater protection against a combined endpoint, while aspirin appeared to provide a smaller additional benefit, particularly when used alongside intensive proton pump inhibition.
These findings are important but require careful interpretation. The study followed participants for years and measured a composite outcome rather than proving that aspirin prevents invasive cancer in every patient. Researchers have also noted questions about dosage, adherence, the balance of benefit and risk, and how the findings should influence routine clinical practice.
| Consideration | What the evidence suggests | Clinical meaning |
|---|---|---|
| Possible benefit | Aspirin may reduce progression-related outcomes in some patients | It remains an individualized option rather than a universal treatment |
| Acid suppression | Proton pump inhibitors are central to reflux management | Aspirin should not be viewed as a substitute for prescribed acid control |
| Main harm | Gastrointestinal bleeding and ulcers are established risks | Bleeding history and interacting drugs require careful review |
| Evidence limitations | Research does not establish equal benefit for all patients | Decisions should reflect age, risk factors, and patient preferences |
Aspirin can irritate the stomach and duodenum and can impair clot formation. The chance of a serious bleed rises with older age, previous ulcers or bleeding, anticoagulant use, corticosteroids, some anti-inflammatory pain medicines, heavy alcohol use, and certain medical conditions. Even low-dose aspirin is not automatically risk-free.
A proton pump inhibitor may reduce upper gastrointestinal complications, but it cannot eliminate bleeding risk. People should also distinguish between aspirin prescribed for cardiovascular prevention and aspirin considered for Barrett’s esophagus. A cardiovascular indication may change the overall balance, while taking aspirin solely for cancer prevention may offer too little benefit for some individuals.
There is no single aspirin regimen appropriate for everyone with Barrett’s esophagus. A clinician may consider the extent of Barrett’s tissue, presence or absence of dysplasia, age, cardiovascular risk, family history, smoking status, reflux control, and anticipated bleeding risk. The condition’s progression risk is also influenced by factors such as male sex, obesity, and a long duration of reflux symptoms.
Endoscopic findings remain central to care. Dysplasia may require closer surveillance, endoscopic eradication therapy, or referral to a specialist team. Aspirin should never delay recommended endoscopy or be used as a reason to overlook new symptoms such as difficulty swallowing, vomiting blood, black stools, or unexplained weight loss.
Aspirin decisions work best as part of a complete management plan. Reflux treatment, weight management where appropriate, tobacco cessation, moderation of alcohol, and adherence to surveillance schedules can all support esophageal health. Nutrition and physical readiness also matter when a person may need an intervention; guidance on nutrition before surgery illustrates how supportive care can complement specialist treatment.
Patients should provide a full medication and supplement list before starting aspirin. This includes anticoagulants, antiplatelet drugs, herbal products, and over-the-counter pain relievers. Any plan should specify the intended dose, monitoring approach, warning symptoms, and circumstances that require stopping or reassessing treatment.
A focused consultation can turn a broad research question into a personalized risk assessment. Useful points to review include:
Aspirin should be started, continued, or stopped only with appropriate medical guidance. People already taking it for heart or vascular disease should not discontinue it abruptly without speaking with the prescribing clinician.
Evidence from gastroenterology research continues to refine the role of chemoprevention in Barrett’s esophagus. Discuss the potential advantages and harms with a gastroenterologist or qualified healthcare professional, and use that conversation to establish a surveillance and treatment plan suited to your individual risk.